Hepatitis C virus (HCV) is a highly prevalent cause of chronic liver disease worldwide, often leading to cirrhosis and hepatocellular carcinoma. HCV is both hepatotropic and lymphotropic, inducing extrahepatic manifestations, like insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus, and also it can affect the lipid metabolism. Recent Advances in biology and medicine have introduced new insights on this issue, making clear some intriguing mechanisms. Knowledge and understanding of these conditions may help improve therapy and provide better care to patients.

We Invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the molecular pathology and the clinical consequences of HCV-induced glucose and lipid metabolism abnormalities, as well as HCV-induced inflammation. We Are particularly interested in articles describing the mechanisms of such abnormalities and their clinical and therapeutic consequences: advances in molecular genetics and molecular diagnostics, small molecules, SiRNA, stem cells, and gene therapy strategies. Potential topics include, but are not limited to:

• Insulin resistance and HCV
• Lipids and HCV
• HCV and cardiovascular risk or disease
• Systemic inflammation and HCV
• HCV and metabolic syndrome
• HCV and immunosuppressive drugs
• HCV and posttransplant recurrence
• HCV, metabolic disorders, and hepatocellular carcinoma
• HCV-associated steatosis
• HCV and the endocrine system

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijhep/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: